Hematologic Malignancies Program

About Hematologic Malignancies Program

Since lymphoma is a cancer of the immune system, a major scientific goal of the Hematologic Malignancies Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.

Program Aims:

  • Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
  • Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
  • Develop New Therapies

Program Directors

Robert K. and Helen K. Summy Professor in the School of Medicine
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, RZ Cao Professor and Professor of Medicine (Hematology)

Program Directory